Hypertension and kidney disease: Is renalase a new player or an innocent bystander?

Journal of Hypertension

Volumn 30, Issue 3, 2012, Pages 457-462

  Malyszko, Jolanta ^a   Malyszko, Jacek S ^a   Mikhailidis, Dimitri P ^b   Rysz, Jacek ^c   Zorawski, Marcin ^a   Banach, MacIej ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

blood pressure; hypertension; kidney diseases; renalase

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATECHOLAMINE; CREATININE; MEMBRANE PROTEIN; NORADRENALIN TRANSPORTER; PROTEIN RENALASE; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1;

BINDING SITE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 84857050190     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834f0bb7     Document Type: Conference Paper

References (62)

1. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115:291-297. (Pubitemid 37088191)
2. Banach M, Rysz J. Current problems in hypertension and nephrology. Expert Opin Pharmacother 2010; 11:2575-2578.
3. Głowińska I, Grochowski J, Małyszko J. Cardiovascular complications in patients with diabetic nephropathy receiving pharmacological versus renal replacement therapy. Pol Arch Med Wewn 2008; 118:404-412.
4. Santos SF, Peixoto AJ. Hypertension in dialysis. Curr Opin Nephrol Hypertens 2005; 14:111-118. (Pubitemid 40396863)
5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-2169. (Pubitemid 37337595)
6. Sarnak MJ, Levey AS. Epidemiology of cardiac disease in dialysis patients. Semin Dial 1999; 12:69-75.
7. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13:1918-1927. (Pubitemid 34700618)
8. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. The rise and fall of hypertension: lessons learned from eastern Europe. Curr Cardiovasc Risk Rep 2011; 5:174-179.
9. Schlaich MP. Sympathetic activation in chronic kidney disease: out of the shadow. Hypertension 2011; 57:683-685.
10. Rahman M, Dixit A, Donley V, Gupta S, Hanslik T, Lacson E, et al. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis 1999; 33:498-506.
11. Mazzuchi N, Carbonell E, Fernández-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58:2147-2154.
12. Salem MM. Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995; 26:461-468.
13. Zoccali C, Mallamaci F, Parlongo S. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359. (Pubitemid 34260428)
14. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tatazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918. (Pubitemid 23006966)
15. Rassaf T, Westenfeld R, Balzer J, Lauer T, Merx M, Floege J, et al. Modulation of peripheral chemoreflex by neurohumoral adaptations after kidney transplantation. Eur J Med Res 2010; 15 (Suppl 2):83-87.
16. Beretta-Piccoli C, Weidmann P, Schiffl H, Cottier C, Reubi FC. Enhanced cardiovascular pressor reactivity to norepinephrine in mild renal parenchymal disease. Kidney Int 1982; 22:297-303. (Pubitemid 12002447)
17. Ishii M, Ikeda T, Takagi M, Sugimoto T, Atarashi K, Igari T, et al. Elevated plasma catecholamines in hypertensives with primary glomerular diseases. Hypertension 1983; 5:545-551. (Pubitemid 13076694)
18. Eisenhofer G, Rundquist B, Aneman A, Friberg P, Dakak N, Kopin IJ, et al. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab 1995; 80:3009-3017.
19. Ziegler MG, Morrissey EC, Kennedy B, Elayan H. Sources of urinary catecholamines in renal denervated transplant recipients. J Hypertens 1990; 8:927-931. (Pubitemid 20368615)
20. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-565. (Pubitemid 36961170)
21. Esler M. The autonomic nervous system and cardiac arrhythmia. Clin Auton Res 1992; 2:133-135.
22. Herzog CA, Ma JZ, Collins AJ. Poor long-term outcome survival after acute myocardial infarction among patients on long-term dialysis. N Eng J Med 1998; 339:799-805. (Pubitemid 28447453)
23. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-574.
24. Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, et al. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 1997; 52:171-181. (Pubitemid 27321828)
25. Shokoji T, Nishiyama A, Fujisawa Y, Hitomi H, Kiyomoto H, Takahashi N, et al. Renal sympathetic nerve responses to tempol in spontaneously hypertensive rats. Hypertension 2003; 41:266-273. (Pubitemid 36204900)
26. Desir GV. Renalase is a novel renal hormone that regulates cardiovascular function. J Am Soc Hypertens 2007; 1:99-103. (Pubitemid 46710832)
27. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005; 115:1275-1280. (Pubitemid 40629046)
28. Hennebry SC, Eikelis N, Socratous F, Desir G, Lambert G, Schlaich M. Renalase, a novel soluble FAD-dependent protein, is synthesized in the brain and peripheral nerves. Mol Psychiatry 2010; 15:234-236.
29. Wang J, Qi S, Cheng W, Li L, Wang F, Li YZ, Zhang SP. Identification, expression and tissue distribution of a renalase homologue from mouse. Mol Biol Rep 2008; 35:613-620.
30. Ghosh SS, Krieg RJ, Sica DA, Wang R, Fakhry I, Gehr T. Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous system. Pediatr Nephrol 2009; 24:367-377.
31. Wu Y, Xu J, Velazquez H, Wang P, Li G, Liu D, et al. Renalase deficiency aggravates ischemic myocardial damage. Kidney Int 2011; 79:853-860.
32. Li G, Xu J, Wang P, Velazquez H, Li Y, Wu Y, Desir GV. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation 2008; 117:1277-1282. (Pubitemid 351365660)
33. Desir G, Tang L, Wang P, Li G, Velazquez H. Antihypertensive effect of recombinant renalase in Dahl salt sensitive (DSS) rats. J Am Soc Nephrol 2010; 21:748A.
34. Zhao Q, Fan Z, He J, Chen S, Li H, Zhang P, Wang L, et al. Renalase gene is a novel susceptibility gene for essential hypertension: a twostage association study in northern Han Chinese population. J Mol Med 2007; 85:877-885. (Pubitemid 47077106)
35. Nugent AC, Bain EE, Thayer JF, Sollers JJ, Drevets WC. Sex differences in the neural correlates of autonomic arousal: a pilot PET study. Int J Psychophysiol 2011; 80:182-191.
36. Stec A, Semczuk A, Furmaga J, Ksiazek A, Buraczynska M. Polymorphism of the renalase gene in end-stage renal disease patients affected by hypertension. Nephrol Dial Transplant 2011. [Epub ahead of print].
37. Farzaneh-Far R, Desir GV, Na B, Schiller NB, Whooley MA. A functional polymorphism in renalase (Glu37Asp) is associated with cardiac hypertrophy, dysfunction, and ischemia: data from the heart and soul study. PLoS One 2010; 5:e13496.
38. Gu R, Lu W, Xie J, Bai J, Xu B. Renalase deficiency in heart failure model of rats: a potential mechanism underlying circulating norepinephrine accumulation. PLoS One 2011; 6:e14633.
39. Wang F, Wang N, Xing T, Cao Y, Xiang H. The cloning and expression of renalase and the preparation of its monoclonal antibody. J Shanghai Jiaotong Univ (Sci) 2009; 14:376-379.
40. Malyszko J, Zbroch E, Malyszko JS, Koc-Zorawska E, Mysliwiec M. Renalase, a novel regulator of blood pressure, is predicted by kidney function in renal transplant recipients. Transplant Proc 2011; 43:3004-3007.
41. Przybylowski P, Malyszko J, Kozlowska S, Malyszko J, Koc-Zorawska E, Mysliwiec M. Serum renalase, depends on kidney function but not on blood pressure in heart transplant recipients. Transplant Proc. (in press)
42. Zbroch E, Malyszko J, Malyszko J, Koc-Zorawska E Mysliwiec M. Renalase in peritoneal dialysis patients is not related to blood pressure, but to dialysis vintage. Perit Dial Int. (in press)
43. Schlaich M, Socratous F, Eikelis N, Chopra R, Lambert G, Hennebry S. Renalase plasma levels are associated with systolic blood pressure in patients with resistant hypertension. J Hypertens 2010; 28:e437.
44. Boomsma F, Tipton KF. Renalase, a catecholamine-metabolising enzyme? J Neural Transm 2007; 114:775-776. (Pubitemid 46980469)
45. Bonaiuto E, Lunelli M, Scarpa M, Vettor R, Milan G, Di Paolo ML. A structure-activity study to identify novel and efficient substrates of the human semicarbazide-sensitive amine oxidase/VAP-1 enzyme. Biochimie 2010; 92:858-868.
46. Noda K, Nakao S, Zandi S, Engelstädter V, Mashima Y, Hafezi-Moghadam A. Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes. Exp Eye Res 2009; 89:774-781.
47. Stolen CM, Madanat R, Marti L, Kari S, Yegutkin GG, Sariola H, et al. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J 2004; 18:702-704.
48. Mercader J, Iffiú-Soltesz Z, Brenachot X, Földi A, Dunkel P, Balogh B, et al. SSAO substrates exhibiting insulin-like effects in adipocytes as a promising treatment option for metabolic disorders. Future Med Chem 2010; 2:1735-1749.
49. Gokturk C, Sugimoto H, Blomgren B, Roomans GM, Forsberg-Nilsson K, Oreland L, Sjoquist M. Macrovascular changes in mice overexpressing human semicarbazide-sensitive amine oxidase in smooth muscle cells. Am J Hypertens 2007; 20:743-750. (Pubitemid 46951021)
50. Lin SY, Wang CC, Lu YL, Wu WC, Hou WC. Antioxidant, antisemicarbazide- sensitive amine oxidase, and antihypertensive activities of geraniin isolated from Phyllanthus urinaria. Food Chem Toxicol 2008; 46:2485-2492.
51. Medvedev AE, Veselovsky AV, Fedchenko VI. Renalase, a new secretory enzyme responsible for selective degradation of catecholamines: achievements and unsolved problems. Biochemistry (Mosc) 2010; 75:951-958.
52. Pandini V, Ciriello F, Tedeschi G, Rossoni G, Zanetti G, Aliverti A. Synthesis of human renalase1 in Escherichia coli and its purification as a FAD-containing holoprotein. Protein Expr Purif 2010; 72:244-253.
53. Luft FC. Renalase, a catecholamine-metabolizing hormone from the kidney. Cell Metab 2005; 1:358-360. (Pubitemid 43960630)
54. Eikelis N, Hennebry SC, Lambert GW, Schlaich MP. Does renalase degrade catecholamines? Kidney Int 2011; 79:1380.
55. Milani M, Ciriello F, Baroni S, Pandini V, Canevari G, Bolognesi M, Aliverti A. FAD-binding site and NADP reactivity in human renalase: a new enzyme involved in blood pressure regulation. J Mol Biol 2011; 411:463-473.
56. Lubas A, Zelichowski G, Prochnicka A, Wisniewska M, Wankowicz Z. Renal autoregulation in medical therapy of renovascular hypertension. Arch Med Sci 2010; 6:912-918.
57. Banach M, Kjeldsen SE, Narkiewicz K. Controversies in hypertension treatment. Curr Vasc Pharmacol 2010; 8:731-732.
58. Malyszko J, Zbroch E, Malyszko J, Mysliwiec M, Iaina A. The cardiorenal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci 2010; 6:539-544.
59. Zbroch E, Malyszko J, Malyszko JS, Koc-Zorawska E, Mysliwiec M. Renalase was not related to blood pressure, but to residual renal function in haemodialysis and peritoneal dialysis patients. J Am Soc Nephrol 2011; 22:723A.
60. Malyszko J, Zbroch E, Malyszko JS, Koc-Zorawska E, Mysliwiec M. Renalase as a possible risk factor of cardiovascular complications in HD. J Am Soc Nephrol 2011; 22:723A-724A.
61. Lubas A, Zelichowski G, Prochnicka A, Wisniewska M, Saracyn M, Wankowicz Z. Renal vascular response to angiotensin II inhibition in intensive antihypertensive treatment of essential hypertension. Arch Med Sci 2010; 6:533-538.
62. Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol 2010; 7:431-441.